Clinical Trials Logo

Acute Exacerbation Copd clinical trials

View clinical trials related to Acute Exacerbation Copd.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT03823443 Recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease

COPD Exacerbation Blood and Urine Biomarkers Study

Start date: June 7, 2018
Phase:
Study type: Observational

This will be a prospective study examining serum levels of MMP-13 and alpha-1 antitrypsin as well as other biomarkers as well as urine biomarkers of smoking status and collagen degradation in the COPD patient population. Serum and urine biomarkers at baseline and after COPD exacerbations will be assessed against change in lung function as measured by pulmonary function testing.

NCT ID: NCT03466385 Recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease

NHF vs NIV in Patients With Acute Exacerbation of COPD

Start date: April 15, 2018
Phase: N/A
Study type: Interventional

Although non-invasive ventilation (NIV) usage has increased significantly over time in COPD exacerbation, a great percentage of patients (~30%) present contraindications to NIV or cannot tolerate it. Nasal high flow (NHF) has been introduced for the management of hypoxemic respiratory failure in adults with favorable effects on ventilation and respiratory mechanics. The above mentioned NHF positive effects has been observed also in stable COPD patients with or without chronic hypercapnia. In this study, the investigators hypothesize that NHF is not inferior to NIV for respiratory support in patients with COPD exacerbation and acute or acute on chronic hypercapnic respiratory failure.

NCT ID: NCT03440060 Recruiting - Clinical trials for Acute Exacerbation Copd

Procalcitonin-guided Antibiotic Therapy During Severe Exacerbation of COPD

Start date: October 5, 2017
Phase: N/A
Study type: Interventional

This study assess whether a procalcitonin guided antibiotic therapy can reduce significantly unnecessary antibiotic prescription during severe exacerbation of COPD requiring mechanical ventilation without compromising patients' outcome. The first group of patients will receive systematically empiric antibiotic therapy and the second group will receive antibiotics only if procalcitonin value is at or greater than 0.25 ng/ml.